<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314935</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 01158-203</org_study_id>
    <nct_id>NCT03314935</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors</brief_title>
  <official_title>A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in
      combination with chemotherapy in participants with advanced/metastatic solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Anticipated">October 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 6, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Participants with treatment-emergent adverse events (TEAE)</measure>
    <time_frame>28 days</time_frame>
    <description>TEAE is defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Objective response rate</measure>
    <time_frame>Every 8 weeks for duration of study participation which is estimated to be 18 months.</time_frame>
    <description>Defined as the percentage of subjects having a complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Participants with TEAEs</measure>
    <time_frame>Screening through 90 days after end of treatment, up to 21 months.</time_frame>
    <description>TEAE is defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Objective response rate</measure>
    <time_frame>Every 8 weeks for duration of study participation, up to 18 months.</time_frame>
    <description>Defined as the percentage of subjects having a CR or PR per RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Every 8 weeks for duration of study participation, up to 18 months.</time_frame>
    <description>Defined as the time from earliest date of CR or PR (per RECIST v1.1) until the earliest date of disease progression or death due to any cause, if occurring sooner than disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Every 8 weeks for duration of study participation, up to 18 months.</time_frame>
    <description>Defined as the percentage of subjects having CR, PR, or stable disease for at least 8 weeks (per RECIST v1.1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Every 8 weeks for duration of study participation, up to 18 months</time_frame>
    <description>Defined as the time from date of first dose of study drug until the earliest date of disease progression (per RECIST v1.1) or death due to any cause, if occurring sooner than progression.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">149</enrollment>
  <condition>Biliary Tract Cancer (BTC)</condition>
  <condition>Colorectal Cancer (CRC)</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Gastroesophageal Cancer (GC)</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB001158 + FOLFOX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB001158 + gemcitabine/cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCB001158 + paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB001158</intervention_name>
    <description>Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.</description>
    <arm_group_label>Treatment Group A</arm_group_label>
    <arm_group_label>Treatment Group B</arm_group_label>
    <arm_group_label>Treatment Group C</arm_group_label>
    <other_name>Arginase inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxaliplatin administered intravenously at the protocol-defined dose and schedule.</description>
    <arm_group_label>Treatment Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Leucovorin at the protocol-defined dose and regimen.</description>
    <arm_group_label>Treatment Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil</intervention_name>
    <description>5-Fluorouracil at the protocol-defined dose and regimen.</description>
    <arm_group_label>Treatment Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine at the protocol-defined dose and regimen.</description>
    <arm_group_label>Treatment Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin at the protocol-defined dose and regimen.</description>
    <arm_group_label>Treatment Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel at the protocol-defined dose and regimen.</description>
    <arm_group_label>Treatment Group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of selected advanced or metastatic
             solid tumors.

          -  Presence of measurable disease per RECIST v1.1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Baseline archival tumor specimen available or willingness to undergo a pretreatment
             tumor biopsy to obtain the specimen.

          -  Resolution of treatment-related toxicities.

          -  Adequate hepatic, renal, cardiac, and hematologic function.

          -  Additional cohort-specific criteria may apply.

        Exclusion Criteria:

          -  Subjects who participated in any other study in which receipt of an investigational
             study drug or device occurred within 28 days or 5 half-lives (whichever is longer)
             prior to first dose.

          -  Has received a prior monoclonal antibody within 4 weeks or 5 half-lives (whichever is
             shorter) before administration of study drug.

          -  Has had prior chemotherapy or targeted small molecule therapy within 2 weeks before
             administration of study treatment.

          -  Has received prior approved radiotherapy within 14 days of study therapy.

          -  Has had known additional malignancy that is progressing or requires active treatment,
             or history of other malignancy within 2 years of study entry.

          -  Has an active autoimmune disease that has required systemic treatment in past 2 years.

          -  Has an active infection requiring systemic therapy.

          -  Has known active CNS metastases and/or carcinomatous meningitis.

          -  Women who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Gogov, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USA Mitchell Cancer Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis - Comprehensive Cancer Centre</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>START San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi - Department of Medical Oncology</name>
      <address>
        <city>Brussels</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet - Clinical Trials Conduct Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Cancer Institute</name>
      <address>
        <city>London</city>
        <zip>WC1E 6BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>INCB001158</keyword>
  <keyword>arginase inhibitor</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>leucovorin</keyword>
  <keyword>5 fluorouracil</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>cisplatin</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>solid tumors</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>biliary tract cancer</keyword>
  <keyword>gastroesophageal cancer</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

